Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: Effect of mutation status on cancer incidence

Breast Cancer Research and Treatment

Volumn 118, Issue 3, 2009, Pages 539-546

  Shah, P ^a   Rosen, M ^a,b   Stopfer, J ^b   Siegfried, J ^c   Kaltman, R ^a,b   Mason, B ^c   Armstrong, K ^a,b   Nathanson, K L ^a,b   Schnall, M ^a,b   Domchek, S M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

Author keywords

BRCA1; BRCA2; MRI; Oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MUTATION; OVARIECTOMY;

EID: 70449604774     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0475-1     Document Type: Article

References (36)

1. A Antoniou PD Pharoah S Narod HA Risch JE Eyfjord JL Hopper, et al. 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 5 1117 1130 10.1086/375033 1:CAS:528:DC%2BD3sXjslagtbg%3D 12677558 (Pubitemid 36530000)
2. MC King JH Marks JB Mandell New York Breast Cancer Study Group 2003 Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 5645 643 646 10.1126/science.1088759 1:CAS:528:DC%2BD3sXotlWqt7Y%3D 14576434 (Pubitemid 37310920)
3. LJ Pierce M Strawderman SA Narod I Oliviotto A Eisen L Dawson, et al. 2000 Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations J Clin Oncol 18 19 3360 3369 1:STN:280:DC%2BD3M%2FgvFWmtQ%3D%3D 11013276
4. SM Domchek BL Weber 2006 Clinical management of BRCA1 and BRCA2 mutation carriers Oncogene 25 43 5825 5831 10.1038/sj.onc.1209881 1:CAS:528: DC%2BD28XhtVSgurjK 16998496 (Pubitemid 44453437)
5. M Robson K Offit 2007 Clinical practice. Management of an inherited predisposition to breast cancer [see comment] N Engl J Med 357 2 154 162 10.1056/NEJMcp071286 1:CAS:528:DC%2BD2sXnslSjsbk%3D 17625127 (Pubitemid 47057733)
6. TR Rebbeck HT Lynch SL Neuhausen SA Narod L Van't Veer JE Garber, et al. 2002 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 21 1616 1622 10.1056/NEJMoa012158 12023993 (Pubitemid 34755669)
7. ND Kauff JM Satagopan ME Robson L Scheuer M Hensley CA Hudis, et al. 2002 Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 21 1609 1615 10.1056/NEJMoa020119 12023992 (Pubitemid 34755668)
8. A Finch M Beiner J Lubinski HT Lynch P Moller B Rosen, et al. 2006 Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation JAMA 296 2 185 192 10.1001/jama.296.2.185 1:CAS:528:DC%2BD28XmvFeiu7w%3D 16835424 (Pubitemid 44050372)
9. A Eisen J Lubinski J Klijn P Moller HT Lynch K Offit, et al. 2005 Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study J Clin Oncol 23 30 7491 7496 10.1200/JCO.2004.00.7138 16234515 (Pubitemid 46291812)
10. TR Rebbeck ND Kauff SM Domchek 2009 Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2 80 87 10.1093/jnci/djn442 1:CAS:528:DC%2BD1MXhtVehsbo%3D 19141781
11. SM Domchek TM Friebel SL Neuhausen T Wagner G Evans C Isaacs, et al. 2006 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 3 223 229 10.1016/S1470-2045(06)70585-X 1:CAS:528:DC%2BD28XitVeitLs%3D 16510331 (Pubitemid 43286452)
12. SR Lakhani JS Reis-Filho L Fulford F Penault-Llorca M van der Vijver S Parry, et al. 2005 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 14 5175 5180 10.1158/1078-0432.CCR-04-2424 1:CAS:528:DC%2BD2MXmt12qtbk%3D 16033833 (Pubitemid 41003703)
13. JL Kramer IA Velazquez BE Chen PS Rosenberg JP Struewing MH Greene 2005 Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers J Clin Oncol 23 34 8629 8635 10.1200/JCO.2005.02.9199 16314625 (Pubitemid 46211505)
14. ND Kauff SM Domchek TM Friebel ME Robson J Lee JE Garber, et al. 2008 Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study J Clin Oncol 26 8 1331 1337 10.1200/JCO.2007.13.9626 18268356
15. E Warner H Messersmith P Causer A Eisen R Shumak D Plewes 2008 Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer Ann Intern Med 148 9 671 679 18458280
16. D Saslow C Boetes W Burke S Harms MO Leach CD Lehman, et al. 2007 American cancer society guidelines for breast screening with MRI as an adjunct to mammography CA Cancer J Clin 57 2 75 89 10.3322/canjclin.57.2.75 17392385 (Pubitemid 46535708)
17. CK Kuhl RK Schmutzler CC Leutner A Kempe E Wardelmann A Hocke, et al. 2000 Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results Radiology 215 1 267 279 1:STN:280:DC%2BD3c3hslajsA%3D%3D 10751498
18. MO Leach CR Boggis AK Dixon DF Easton RA Eeles DG Evans, et al. 2005 Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) Lancet 365 9473 1769 1778 10.1016/S0140-6736(05)66481-1 1:STN:280:DC%2BD2M3mvFCqtg%3D%3D 15910949 (Pubitemid 40744657)
19. E Warner DB Plewes KA Hill PA Causer JT Zubovits RA Jong, et al. 2004 Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination JAMA 292 11 1317 1325 10.1001/jama.292.11.1317 1:CAS:528:DC%2BD2cXns12rs78%3D 15367553 (Pubitemid 39223222)
20. CD Lehman C Isaacs MD Schnall ED Pisano SM Ascher PT Weatherall, et al. 2007 Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study Radiology 244 2 381 388 10.1148/radiol.2442060461 17641362 (Pubitemid 47080869)
21. M Kriege CT Brekelmans C Boetes PE Besnard HM Zonderland IM Obdeijn, et al. 2004 Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition N Engl J Med 351 5 427 437 10.1056/NEJMoa031759 1:CAS:528:DC%2BD2cXmtFalu7o%3D 15282350 (Pubitemid 38988592)
22. F Laki YM Kirova P This C Plancher B Asselain X Sastre D Stoppa-Lyonnet R Salmon for the IC-BOCRSG IC-BOCRSG: Institut Curie -Breast Ovary Cancer Risk Study Group 2007 Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation Cancer 109 9 1784 1790 10.1002/cncr.22603 1:CAS:528:DC%2BD2sXlsF2ntbY%3D 17351952 (Pubitemid 46668541)
23. K Metcalfe HT Lynch P Ghadirian N Tung I Olivotto E Warner, et al. 2004 Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers J Clin Oncol 22 12 2328 2335 10.1200/JCO.2004.04.033 1:CAS:528:DC%2BD2cXpsVWltbs%3D 15197194 (Pubitemid 41115389)
24. TR Rebbeck AM Levin A Eisen C Snyder P Watson L Cannon-Albright, et al. 1999 Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers J Natl Cancer Inst 91 17 1475 1479 10.1093/jnci/91.17.1475 1:STN:280:DyaK1MvgtVyisw%3D%3D 10469748
25. HM Klaren LJ van't Veer FE van Leeuwen MA Rookus 2003 Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation [see comment] J Natl Cancer Inst 95 13 941 947 12837830
26. MC King S Wieand K Hale M Lee T Walsh K Owens, et al. 2001 Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial JAMA 286 18 2251 2256 10.1001/jama.286.18.2251 1:CAS:528:DC%2BD3MXosFCktr8%3D 11710890
27. SA Narod JS Brunet P Ghadirian M Robson K Heimdal SL Neuhausen, et al. 2000 Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group Lancet 356 9245 1876 1881 10.1016/S0140-6736(00)03258-X 1:CAS:528:DC%2BD3cXovFWjsL8%3D 11130383
28. J Gronwald N Tung WD Foulkes K Offit R Gershoni M Daly, et al. 2006 Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update Int J Cancer 118 9 2281 2284 10.1002/ijc.21536 1:CAS:528:DC%2BD28XjsVCgt7Y%3D 16331614
29. WD Foulkes K Metcalfe P Sun WM Hanna HT Lynch P Ghadirian, et al. 2004 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type Clin Cancer Res 10 6 2029 2034 10.1158/1078-0432.CCR-03-1061 1:CAS:528:DC%2BD2cXisVGlu7c%3D 15041722 (Pubitemid 38375563)
30. SR Lakhani MJ Van De Vijver J Jacquemier TJ Anderson PP Osin L McGuffog, et al. 2002 The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 9 2310 2318 10.1200/JCO.2002.09.023 1:CAS:528:DC%2BD38XktVKrs7o%3D 11981002 (Pubitemid 34441658)
31. RB Clarke A Howell CS Potten E Anderson 1997 Dissociation between steroid receptor expression and cell proliferation in the human breast Cancer Res 57 22 4987 4991 1:CAS:528:DyaK2sXnsV2ktrY%3D 9371488
32. N Zeps JM Bentel JM Papadimitriou MF D'Antuono HJ Dawkins 1998 Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth Differentiation 62 5 221 226 10.1046/j.1432-0436.1998.6250221.x 1:CAS:528:DyaK1cXislagur4%3D 9566307 (Pubitemid 28165705)
33. B Evers J Jonkers 2006 Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects Oncogene 25 43 5885 5897 10.1038/sj.onc.1209871 1:CAS:528:DC%2BD28XhtVSgurvL 16998503 (Pubitemid 44453444)
34. WD Foulkes IM Stefansson PO Chappuis LR Begin JR Goffin N Wong, et al. 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 19 1482 1485 1:CAS:528:DC%2BD3sXnvVCjtrk%3D 14519755
35. MM Tilanus-Linthorst CC Bartels AI Obdeijn M Oudkerk 2000 Earlier detection of breast cancer by surveillance of women at familial risk Eur J Cancer 36 4 514 519 10.1016/S0959-8049(99)00337-8 1:STN:280: DC%2BD3c3gvV2nuw%3D%3D 10717529 (Pubitemid 30136231)
36. SK Plevritis AW Kurian BM Sigal BL Daniel DM Ikeda FE Stockdale, et al. 2006 Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging JAMA 295 20 2374 2384 10.1001/jama.295.20.2374 1:CAS:528:DC%2BD28Xlt1WksL8%3D 16720823 (Pubitemid 43788105)